Compare MITT & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITT | PEPG |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.5M | 207.1M |
| IPO Year | 2011 | 2022 |
| Metric | MITT | PEPG |
|---|---|---|
| Price | $6.82 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $9.25 | ★ $11.17 |
| AVG Volume (30 Days) | 285.1K | ★ 994.9K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 11.96% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.48 | N/A |
| Revenue Next Year | $5.06 | N/A |
| P/E Ratio | $676.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.93 | $1.31 |
| 52 Week High | $9.27 | $7.80 |
| Indicator | MITT | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 62.20 |
| Support Level | $6.53 | $1.47 |
| Resistance Level | $8.00 | $3.14 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 85.48 | 37.41 |
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.